Fezolinetant ( Veoza ) Now Available on the NHS: A New Non Hormonal option for hot flushes and sweats
The NHS has just announced the availability of Fezolinetant, a groundbreaking treatment designed to alleviate some of the most common symptoms of the menopause. This approval marks a significant advancement in the management of menopausal symptoms, particularly for those women who struggle with vasomotor symptoms such as hot flushes and night sweats. It will currently only be available in England, Wales and Northern Ireland.
What is Fezolinetant?
Fezolinetant ( also known as Veoza ) is a once a day oral tablet that works as a selective neurokinin-3 receptor antagonist. By targeting specific receptors in the brain, it effectively reduces the frequency and severity of hot flushes, providing much-needed relief for women experiencing this challenging phase of life. Fezolinetant offers a new non-hormonal alternative for those who can’t use HRT for medical reasons or choose not to use it, making it a suitable option for many women.
Why is This Important?
Menopause is a natural biological process that typically occurs between the ages 45 and 55, resulting in the end of periods and some women will see the development of symptoms due to hormonal changes. Many women experience vasomotor symptoms, leading to significant discomfort and deterioration in their quality of life. Despite the availability of HRT, a substantial number of women either can’t use hormonal treatments due to personal health risks or prefer to avoid them altogether. The introduction of Fezolinetant provides a new option, filling a vital gap in menopause treatment options, and could prove very useful for anyone who has had breast cancer previously.
NHS Approval and Impact
The NHS's decision to incorporate Fezolinetant into its treatment offerings comes after a thorough assessment of its efficacy and safety. Clinical trials demonstrated that Fezolinetant significantly reduced the frequency and intensity of hot flushes, with many participants reporting high levels of satisfaction with the treatment. The NHS's approval means that eligible women can now access this medication.
This step is expected to transform menopause management for thousands of women across the UK. With menopause affecting roughly half of the population, the introduction of effective non-hormonal treatment options can empower women to manage their symptoms more effectively, reducing reliance on traditional therapies that may not be suitable for everyone.
Accessing Fezolinetant
Women interested in Fezolinetant should consult with their GP or healthcare provider to discuss their symptoms and determine if this new treatment is appropriate for them. As with any medication, it’s essential to consider individual health histories and any potential contraindications.
The NHS now aims to ensure that Fezolinetant is accessible to those who would benefit from it.
Add comment
Comments